C-CAR088

BIOLOGICAL5 trials

Sponsors

Hebei Yanda Ludaopei Hospital, The First Affiliated Hospital with Nanjing Medical University, Peking Union Medical College Hospital, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Multiple MyelomaRelapsed or Refractory Multiple Myeloma

Phase 1

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Hebei Yanda Ludaopei HospitalRelapsed or Refractory Multiple Myeloma

Start: 2019-01-08End: 2020-10-30Target: 10Updated: 2019-05-15

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

The First Affiliated Hospital with Nanjing Medical UniversityRelapsed or Refractory Multiple Myeloma

Start: 2019-04-11End: 2021-04-30Target: 12Updated: 2019-07-05

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Peking Union Medical College HospitalMultiple Myeloma

Start: 2019-10-23End: 2021-12-31Target: 10Updated: 2020-03-04

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

CompletedNCT04322292

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma

Start: 2019-09-12End: 2022-09-22Updated: 2026-02-11

ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

RecruitingNCT05632380

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma

Start: 2022-07-14End: 2026-10-30Target: 20Updated: 2026-08-07

Related Papers

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood2024-11-052 citations

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood2023-11-021 citations

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

Journal for ImmunoTherapy of Cancer2022-09-0131 citations

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Blood2021-11-054 citations

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Blood2020-11-0421 citations

Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma

Blood2019-11-1314 citations